$0.59
Live
1.69%
Downside
Day's Volatility :7.17%
Upside
5.57%
73.64%
Downside
52 Weeks Volatility :99.1%
Upside
96.57%
Period | Altamira Therapeutics Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -45.87% | 0.0% |
6 Months | -57.86% | 0.0% |
1 Year | -82.34% | 0.0% |
3 Years | -99.92% | -23.0% |
Market Capitalization | 2.4M |
Book Value | $2.37 |
Earnings Per Share (EPS) | 1.82 |
PE Ratio | 0.34 |
Wall Street Target Price | 5.29 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -57.15% |
Return On Equity TTM | -368.78% |
Revenue TTM | 120.3K |
Revenue Per Share TTM | 0.92 |
Quarterly Revenue Growth YOY | -63.7% |
Gross Profit TTM | -2.2M |
EBITDA | -5.8M |
Diluted Eps TTM | 1.82 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.07 |
EPS Estimate Next Year | -1.36 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 796.61%
Sell
Neutral
Buy
Altamira Therapeutics Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Altamira Therapeutics Ltd | -11.68% | -57.86% | -82.34% | -99.92% | -99.95% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Altamira Therapeutics Ltd | 0.34 | 0.34 | NA | -3.07 | -3.69 | -0.57 | NA | 2.37 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Altamira Therapeutics Ltd | Buy | $2.4M | -99.95% | 0.34 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Altamira Therapeutics Ltd
Revenue is up for the last 3 quarters, -458.69K → 52.73K (in $), with an average increase of 484.9% per quarter
Netprofit is up for the last 3 quarters, -9.61M → -2.71M (in $), with an average increase of 127.3% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 165.4%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 144.7%
UBS Group AG
Morgan Stanley - Brokerage Accounts
altamira therapeutics (former auris medical) is dedicated to developing therapeutics that address important unmet medical needs. the company is currently active in three areas: • the development of rna therapeutics for extrahepatic therapeutic targets (oligophore™ / semaphore™ platforms; preclinical), • nasal sprays for protection against airborne viruses and allergens (bentrio™; commercial) or the treatment of vertigo (am-125; phase 2) • the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (keyzilen® and sonsuvi®, phase 3). the company was founded in 2003, under the name auris medical, and is headquartered in hamilton, bermuda with its main operations in basel, switzerland. the shares of altamira therapeutics ltd. trade on the nasdaq capital market under the symbol “cyto.”
Organization | Altamira Therapeutics Ltd |
Employees | 10 |
CEO | Dr. Thomas Meyer Ph.D. |
Industry | Miscellaneous |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.59
+0.0%
Invesco Bulletshares 2025 Hi
$0.59
+0.0%
Schwab International Dividend Equity Etf
$0.59
+0.0%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.59
+0.0%
Lightpath Technologies Inc
$0.59
+0.0%
Vaneck Vectors Global Alternative Energy Etf
$0.59
+0.0%
First Trust Flexible Municipal High Income Etf
$0.59
+0.0%
Drx Dly Reg Bank Bull 3x
$0.59
+0.0%
Graniteshares 2x Long Pltr Daily Etf
$0.59
+0.0%